A REVIEW ON CURRENT STRATEGIES OPTED BY REGULATORY BODIES FOR INDIAN CLINICAL TRIALS
Khushwant Khatri*, Priyanka Modi and Khushbu Shah
ABSTRACT
Currently India is the major hub of Asian country which conducts
various multicentre clinical trials. The conduct of these clinical trials is
being critically reviewed at both national and international platforms.
The Regulatory Bodies of India is upgrading the quality of the Clinical
trials to meet up the international standards. It is essential that now all
clinical trials conducted in India should as per the International
conference of Harmonization-Good Clinical Practices Guidelines
(ICH-GCP) for clinical trials and follow the recently amended
Schedule Y of the Drugs and Cosmetics Act. The regulatory guidelines
in terms of serious adverse events (SAEs) reporting, audio-visual (AV)
consulting, informed consent, compensation in case of injury or death
in clinical trials have been currently modified. This article provides an
insight into the recent changes with respect to the regulations of clinical trials and its impact
on the clinical research industry in India.
Keywords: Regulatory bodies, Clinical Trial, DCGI and CDSCO.
[Full Text Article]